| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
26S proteasome and microtubules. NSC 601980 is reported as a 26S proteasome inhibitor that blocks proteasome-mediated protein degradation, leading to protein accumulation and apoptosis in tumor cells. It may also act as a microtubule-disrupting agent, interfering with microtubule assembly.
|
|---|---|
| ln Vitro |
NSC 601980 effectively inhibits cell proliferation in COLO 205 and HT29 cell lines with Log GI50 values of -6.6 and -6.9 respectively, demonstrating antitumor potency in yeast screening assays.
|
| ln Vivo |
No specific in vivo data reported; however, based on its anti-proliferative activity in vitro, it is suggested to induce tumor growth inhibition in xenograft models. Further in vivo validation studies are needed.
|
| Enzyme Assay |
NSC 601980 is dissolved in DMSO to prepare stock solutions. For binding studies, the compound is incubated with purified 26S proteasome or tubulin at concentrations ranging from 0.1-100 uM in assay buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 1 mM ATP) for 30-60 min at 37degC. Proteasome activity is measured using fluorogenic substrates (e.g., Suc-LLVY-AMC). Inhibition of tubulin polymerization can be assessed spectrophotometrically at 340 nm.
|
| Cell Assay |
COLO 205 or HT29 cells are seeded in 96-well plates at 5×103 cells/well and treated with NSC 601980 (0.1-100 microM) for 48-72 h. Cell viability is assessed using MTT or CellTiter-Glo assay. GI50 values are calculated by nonlinear regression. Apoptosis induction can be confirmed by Annexin V/PI staining followed by flow cytometry.
|
| Animal Protocol |
No in vivo animal study protocols are specifically documented. Based on similar antitumor compounds, a typical regimen might involve intraperitoneal or intravenous administration at doses ranging from 5-50 mg/kg daily or every other day for 2-3 weeks in immunodeficient mice bearing tumor xenografts. Endpoints include tumor volume measurement, body weight monitoring, and terminal histopathology. Researchers should design pilot studies to establish appropriate dosing.
|
| ADME/Pharmacokinetics |
Cannot be extracted; information not available. For this compound, no pharmacokinetic data has been published. Investigators are advised to conduct their own PK studies: typical approaches include LC-MS/MS analysis of plasma samples after IV or PO administration to determine key parameters such as half-life (t1/2), clearance (CL), volume of distribution (Vd), and oral bioavailability (F%).
|
| Toxicity/Toxicokinetics |
NSC 601980 has not undergone standard toxicity testing. It is intended for research use only. Based on its mechanism as a proteasome inhibitor, potential toxicities may include gastrointestinal and hematologic effects, similar to clinically used proteasome inhibitors, but these have not been formally evaluated for this specific analog.
|
| References |
[1]. DTP Datawarehouse Index Results.
|
| Additional Infomation |
NSC 601980 is available in high purity (≥95%) for research purposes. The exact IUPAC name is (3-methylquinoxalin-2-yl)-phenyldiazene. Synonyms include 3-methylquinoxalin-2-yl)-phenyldiazene. Molecular formula: C15H12N4; molecular weight: 248.28. It is not approved for clinical use.
|
| Molecular Formula |
C15H12N4
|
|---|---|
| Molecular Weight |
248.28
|
| Exact Mass |
248.106
|
| CAS # |
2070018-27-6
|
| Related CAS # |
NSC 601980 (analog);91757-46-9
|
| PubChem CID |
121230984
|
| Appearance |
Pink to red solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
420.2±45.0 °C at 760 mmHg
|
| Flash Point |
207.9±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.658
|
| LogP |
3.76
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
311
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C2C(=CC=CC=2)N=C(N=NC2=CC=CC=C2)C=1C
|
| InChi Key |
HUXPPDSCOMVLMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H12N4/c1-11-15(19-18-12-7-3-2-4-8-12)17-14-10-6-5-9-13(14)16-11/h2-10H,1H3
|
| Chemical Name |
(3-methylquinoxalin-2-yl)-phenyldiazene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (100.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0277 mL | 20.1386 mL | 40.2771 mL | |
| 5 mM | 0.8055 mL | 4.0277 mL | 8.0554 mL | |
| 10 mM | 0.4028 mL | 2.0139 mL | 4.0277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
